Injection Of Testosterone Research Articles

8637 Pituicytoma mimicking Craniopharyngioma

Abstract Disclosure: O. Araoye: None. T. Delibasi: None. A. Chaugule: None. S.K. Dhillon: None. C. Fuller: None. Pituicytoma, a rare low-grade glial tumor originating from the neurohypophysis or infundibulum of the pituitary gland, poses diagnostic challenges due to its propensity to mimic other sellar or suprasellar lesions. We present a case of a 51-year-old male with a history of a suprasellar mass initially suggested to be a craniopharyngioma, incidentally discovered. Opting for elective surgery, the patient underwent transsphenoidal resection, revealing a highly vascular tumor adherent to the optic chiasm and pituitary stalk. While the tumor was successfully removed, sacrifice of the pituitary stalk led to postoperative complications, including cerebrospinal fluid (CSF) leak and central diabetes insipidus (DI).Histopathological examination characterized the tumor as oncocytic pituicytoma/spindle cell oncocytoma, a subtype of pituicytoma. The anti-mitochondrial antibody staining at an external laboratory displayed diffuse granular cytoplasmic staining supporting oncocystic pituicytoma/spindle cell oncocytoma.Postoperatively, the patient developed central DI treated initially with desmopressin (DDAVP), complicated by subsequent hyponatremia necessitating salt tablets and fluid restriction. Additionally, central adrenal insufficiency was managed with hydrocortisone, and central hypothyroidism with levothyroxine. A history of testosterone deficiency was addressed through testosterone injections every 10 weeks.Pituicytoma's diagnostic complexity arises from nonspecific radiological features, requiring reliance on histology and immunohistochemistry for definitive diagnosis. The expression of TTF1 emerges as a characteristic marker. Surgical resection, the primary treatment modality, proves curative in most cases, albeit with associated morbidity including CSF leak, DI, and panhypopituitarism. The role of adjuvant radiotherapy remains uncertain, potentially considered in cases of incomplete resection or recurrence.This case emphasizes three key aspects: first, the potential misdiagnosis of a lobulated suprasellar mass as craniopharyngioma when it could be pituicytoma; second, the development of postoperative DI due to pituitary stalk involvement; and third, the importance of considering pituicytoma in the differential diagnosis of sellar and suprasellar masses.In conclusion, pituicytoma, though rare, demands a nuanced diagnostic approach and comprehensive postoperative management to address potential complications and optimize patient outcomes. Presentation: 6/2/2024

7275 Diverse Reasons for Discontinuing Gender Affirming Hormone Therapy

Abstract Disclosure: A. Jain: None. M.S. Irwig: None. Many Transgender and Gender Diverse (TGD) individuals take Gender Affirming Hormone Therapy (GAHT). A study that included 264 adults [67% assigned male at birth (AMAB)] in Georgia found that 2% (n=5) discontinued GAHT over a follow-up period of 64 months. Reasons identified were change in gender identity (n=2), financial barriers (n=2) and venous thrombosis (n=1). Discontinuation was temporary for 2 and permanent for 2. Here we describe the reasons why four TGD individuals discontinued GAHT. Case Descriptions: Patient 1, AMAB, came out as gay as a teenager. In his mid 30s he became unhappy which he attributed to a conflict between religion and his sexual orientation and failed relationships. He thought that changing his sex would solve his problems. He took injectable estrogen for 3-4 years. He subsequently underwent multiple gender-affirmation surgeries including facial feminization surgery, breast implants, an orchiectomy and vaginoplasty. Immediately following the breast implant surgery he had regrets and wanted them removed. He also regretted the vaginoplasty. He stopped estrogen following the bottom surgery. In his 40s he stated that he would like to detransition as he sees himself "as a fake" when looking in the mirror. Patient 2 was assigned female at birth. Puberty was associated with discomfort from having a large chest. In his late 20s he began injectable testosterone which he took for three years. He then decided to take a two year break as he was frustrated that he had not achieved the desired results and because he was still not able to pass as a man. He resumed testosterone two years ago and underwent top surgery. Patient 3, AMAB, knew from a young age that he was transgender. He took estrogen and an antiandrogen for > 5 years and underwent an orchiectomy and vaginoplasty. He was pleased with the results from the GAHT and surgeries. He presented as a woman for many years. A few years ago, however, he awoke one day with the thought that God wanted him to be a man. He decided to detransition and presented to the endocrinology clinic to start testosterone therapy. Patient 4, AMAB, began GAHT in her late 30s. She discontinued GAHT 4 years later due to lack of results (feminization, larger breasts, wider hips and a more curvy figure). She presented to the endocrinology clinic 2 years later, wanting to resume GAHT. Conclusion: In addition to the reasons identified by Gupta et al for discontinuation of GAHT, we also identified unrealistic expectations, not achieving the desired results and perceived conflict between religion and gender identity. Endocrinologists should be aware of the possibility of discontinuation of GAHT and know how to manage any potential complications such as hypogonadism that may arise. Reference: Gupta P et al. J Clin Endocrinol Metab. 2023. Presentation: 6/2/2024

Persistent menstruation in transgender people using testosterone gender-affirming hormone therapy

Background The cessation of menstruation is a common and desired outcome of testosterone gender-affirming hormone therapy (GAHT), for trans and gender diverse (collectively referred to as trans) individuals recorded female at birth. This study aimed to (a) assess the prevalence and characteristics of menstruation before and after commencing testosterone GAHT, and (b) explore factors associated with persistent menstruation. Method Trans people using testosterone therapy for gender affirmation, aged ≥16 years and living in Australia completed an online cross-sectional survey between 28 August to 31 December 2020. Multivariable logistic regression analysis was applied to estimate the effect size of factors potentially contributing to the cessation or persistence of menstruation 6 months after starting testosterone therapy. Results There were 401 eligible respondents. Median age for commencement of testosterone GAHT was 23 years (IQR = 20, 28) and the median duration of testosterone therapy was 37 months (IQR = 19, 65). Intramuscular testosterone undecanoate injections were the most used formulation. Persistent menstruation >6 months after commencing testosterone GAHT was reported by 87 (22.8%) participants. The odds of reporting persistent menstruation >6 months after commencing testosterone were (a) higher in people using testosterone gels/creams compared to testosterone injections (OR = 11.3 [1.1, 118.2]), and (b) lower in individuals with a body mass index ≥30 kg/m2 versus <30 kg/m2 (OR = 0.5 [0.3, 0.99]). No association was found between persistent menstruation >6 months after commencing testosterone and (a) menstrual regularity prior to commencing testosterone GAHT, and (b) age at commencement of treatment. Conclusion Persistent menstruation >6 months after commencing testosterone GAHT may be impacted by body mass index and the mode of testosterone administration. This is important information for individuals considering testosterone GAHT as well as for clinicians advising on the benefits and drawbacks of different forms of testosterone administration as well as the likelihood of menstrual cessation.

Testosterone in Puberty Regulates Emotional Contagion and Consolation via the Vasopressin System in the Anterior Cingulate Cortex of C57BL/6J Mice

Introduction: Empathy is the ability of an individual to present and respond to the emotions of others and is thought to originate from parental behavior. Testosterone could promote aggression and inhibit biparental behavior and vasopressin (AVP) could promote aggression. Given levels of aggression and parental care are closely associated with levels of empathy, we hypothesized that testosterone may influence empathetic behavior via the AVP system. Methods: We examined testosterone levels and tested social, empathic, and anxiety-like behaviors after castration surgery to pubertal mice, and subsequently examined the molecular levels of AVP, V1aR in different brain regions. Finally, pharmacological experiments were used to test the effects on empathic behavior by injecting testosterone in combination with V1aR antagonist. Results: Here, we show that pubertal castration reduced serum testosterone levels, increased empathetic behavior and sociality, and reduced anxiety-like behaviors in male C57 mice. The pubertal castration also reduced AVP and vasopressin receptor (V1aR) protein levels, and AVP mRNA levels in the PVN. It also reduced the number of AVP-positive neurons in the PVN. In addition, pubertal subcutaneous injection of testosterone reduced emotional contagion and consolation of castrated mice, while concomitant injection of V1aR antagonists into the anterior cingulate cortex (ACC) reversed the downregulation of emotional contagion and consolation induced by testosterone. Conclusion: It is suggested that testosterone in puberty regulates empathetic behavior in C57 mice possibly via the AVP system in the ACC. These findings help us to understand the neuroendocrine mechanisms underlying empathetic behavior and provide potential targets for the treatment of psychiatric disorders associated with low empathy.

The Effect of Testosterone on Serum Lipid Profiles, Glucose, Insulin and Leptin: A Experimental Study Based Animal Model

Background: Disruption in the endocrine system can cause many diseases. Based on this, the imbalance of sex hormones such as testosterone can change many serum factors. In this study, we examined the effect of testosterone on leptin levels, lipid profiles, and ultimately insulin resistance. Materials and Methods: Twenty one adult rats were divided into three groups of 7, including control group (C), olive oil group (O), and olive oil and testosterone group (OT). In the O and OT groups, they received olive oil and olive oil in combination with testosterone injection at the dose of 2 mg/kg/day, respectively. To evaluate the effects of hormonal imbalance on insulin resistance, various parameters such as leptin, triglyceride, cholesterol, glucose, and insulin were assessed. Results: The results showed that Triglyceride (TG) and insulin levels were higher in the OT group compared to the other two groups (P&lt;0.05). In contrast, leptin and cholesterol levels were higher in group C compared to the other two groups (P&lt;0.05) and glucose levels were higher in group O compared to the other two groups (P=0.01). Conclusion: In general, it can be said that testosterone can change serum lipid profiles, leptin, insulin, and glucose.

Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review.

Approximately, 11% of trans men experience erythrocytosis diagnosis due to testosterone administration during the first year of the gender-affirming hormone treatment (GAHT). To identify and compare the effect of different testosterone formulations on hematocrit (Hct) and diagnose erythrocytosis in trans men. This systematic review was based on PRISMA guidelines. We performed an electronic search of PubMed, Embase, and Web of Science in January 2024. The Newcastle-Ottawa scale was used to evaluate the quality of evidence in the observational studies. Of the 152 records retrieved, 18 met the eligibility criteria. Studies observed an increase of up to 5% in Hct in trans men using injectable testosterone undecanoate (TU), and up to 6.9% in trans men using intermediate injectable testosterone esters (TE). Trans men using TE experience a larger increase in serum Hct levels compared to those receiving TU. Erythrocytosis prevalence varies according to the cutoff used (50%, 52%, and 54%). Erythrocytosis was also associated with tobacco use, age at initiation of hormone therapy, body mass index (BMI), and pulmonary conditions. Studies that evaluated the effect of testosterone formulation on erythrocytosis diagnosis present conflicting result. Trans men have a hazard ratio of 7.4 (95% CI: 4.1, 13.4) of developing erythrocytosis compared to cisgender men, using a 52% hematocrit cutoff. All testosterone formulations result in an increase in Hct, irrespective of dose, formulation, and administration method. Smoking, higher age at initiation of the testosterone therapy, higher BMI, and a predisposing medical history are associated with this increase in Hct. The difference in effect of TE and TU on Hct is conflicting, although it is important to point out that these data come from observational studies, retrospective, and with a small-sample size.

Recent Developments in Promising Hormonal and Non- Hormonal Male Contraceptives: A Review

New male contraceptive methods would expand male and female contraceptive alternatives and enhance male contraceptive agency. Since 1969, a program for developing contraceptives has been financed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, which also continues to fund the majority of hormonal male contraceptive development today. Also, the early stages of non-hormonal techniques start to develop. The hormonal male contraceptive methods, include testosterone undecanoate injection plus norethisterone enanthate injection, implants of testosterone plus depo-medroxyprogesterone acetate injection, testosterone enanthate injection, and other testosterone-based methods. The non-hormonal methods, include novel hormone-free substances such as retinoic acid inhibitors, sperm ion channel blockers, and vasal peristalsis blockers. The review provides insights into the efficacy, safety, and potential side effects of each method, and highlights the current state of research and development in the field of male contraception.

Remediation of prostrate-related disorders using polyphenols: kolaviron and quercetin in perspective

The study aimed to examine the effects of kolaviron and quercetin on testosterone-induced benign prostatic hyperplasia (BPH) in Wistar rats. Fifty rats weighing between 250g and 300g were selected, with forty-two rats being divided into six groups of seven each. The first group served as the control and received 0.5ml of Canola oil. The remaining groups were induced with BPH using a 5mg/kg body weight testosterone injection for four weeks. After BPH induction, the second group received 0.5ml of Canola oil, while the third, fourth, fifth, and sixth groups were treated with 150mg/kg body weight Kolaviron, 15mg/kg body weight Quercetin, 150mg/kg body weight Kolaviron combined with 15mg/kg body weight Quercetin, and 5mg/70kg body weight finasteride for twenty-eight days. BPH induction notably increased levels of various biomarkers such as malondialdehyde, total protein, albumin, globulin, total bilirubin, conjugated bilirubin, total cholesterol, triglycerides, LDL-c, and VLDL-c compared to the control group. However, treatment with Kolaviron and Quercetin effectively reversed these elevations. Notably, the Quercetin group did not exhibit significant differences in triglyceride levels compared to the BPH-induced group. BPH induction also led to a significant reduction in HDL-c levels compared to the control group, which was reversed by Kolaviron and Quercetin treatment. In conclusion, the findings suggest the potential of utilizing kolaviron and quercetin for the treatment of prostate-related conditions

Injectable testosterone PLGA microsphere with different characteristics: effect of preparation method (paddle mixing versus microfluidic device)

The purpose of this study was to compare the characteristics of testosterone polylactic-co-glycolic (PLGA) microspheres prepared by a paddle mixer or microfluidics device. The comparison was conducted by not only in vitro evaluation but also in vivo evaluation which has not been reported up to date. We discovered that, among the steps in microsphere preparation, the solvent removal process strongly impacted drug content, particle size and surface morphology. Spectroscopic measurements suggested that molecular interactions and crystallinity of the drug incorporated in the microspheres differed. For the drug release profile, although both mixer- and microfluidics-prepared samples showed similar sustained release of the incorporated drug for approximately one month in vitro, they exhibited different plasma concentration profiles in vivo. Together, our findings show that the preparation process, especially the solvent removal process, may affect the physicochemical characteristics of testosterone PLGA microspheres, leading to different in vivo performance.

A Study on The effect of Testosterone on Liver and Kidney functions of Male Rabbits

The purpose of this study was to examine the effect of two supraphysiological doses of testosterone on the liver and kidney functions of male rabbits. Fifteen (15) adult male rabbits were divided into 3 groups: a control group (received 100 µl sesame oil), a low dose group (received 6 mg testosterone/kg body weight), and a high dose group (received 12 mg testosterone/kg body weight). The rabbits were injected intramuscularly once a week for 6 weeks. After the end of the treatment period, the rabbits were sacrificed and blood samples were collected for analysis. Injection of testosterone resulted in a significant increase in the level of this hormone in the sera of the treated rabbits. The hormone caused increases in the levels of the liver function enzymes with the increase in dose; however, only the high dose caused statistically significant increases. Similar trend was observed with the effect of the hormone on the concentrations of creatinine and urea, where only the high dose had a statistically significant effect. These results clearly indicate that the use of this hormone with high doses for long periods could cause damage to the liver and kidney.

Title: Influence of the NASA SPRINT exercise protocol on myonuclear and satellite cell content of the vastus lateralis and soleus during 70 days of bedrest

Objectives: The purpose of this study was to assess the effcacy of the NASA SPRINT exercise protocol in preserving myonuclear and satellite cell number of the quadriceps (vastus lateralis) and triceps surae (soleus) muscles following 70 days of bedrest (i.e., simulated microgravity). These two muscles were the focus of this study because they both atrophy significantly with microgravity exposure in the absence of countermeasures. Hypotheses: The SPRINT exercise protocol will preserve myonuclear number (MNN), myonuclear domain (MND), and satellite cell number (SCN) during 70 days of bedrest. Methods: Subjects were randomized into three groups: bedrest only (BR; n=8, 37±3 y), bedrest with endurance and resistance exercise (BRE; n=9, 34±2 y) and bedrest with endurance and resistance exercise and low dose testosterone injections (BRE+T; n=8, 33±3 y). Muscle biopsies were taken before and at the end of bedrest from the vastus lateralis and soleus, and were sectioned, immunofluorescently stained, and analyzed for MNN (myonuclei/fiber), MND (μm2/myonuclei), and SCN (satellite cells/fiber) in slow (myosin heavy chain (MHC) I) and fast (MHC IIa) muscle fibers. SCN was only determined in MHC I fibers for the soleus. Results: MNN, MND, and SCN in MHC I and IIa fibers of the vastus lateralis and soleus were unchanged (p&lt;0.05) from pre- to post-bedrest within BR, BRE, and BRE+T. However, there was a main effect for time (p&lt;0.05) for a decrease in MND for vastus lateralis MHC I fibers (-8%), as well as soleus MHC I (-18%) and IIa (-18%) fibers. Also, there was a trend for a main effect for time (P=0.059) for an increase (+37%) in SCN for vastus lateralis MHC IIa fibers, which was driven primarily by the exercise groups (BR: -4%, BRE: +36%, BRE+T: +67%). Conclusions: Myonuclear number appears to be unaltered during 70 days of simulated microgravity with or without countermeasures exercise. As a result, any changes in myonuclear domain correspond with alterations in muscle mass. Satellite cell number also appears to be relatively refractory to change, but may be influenced in fast muscle fibers under the combined dynamic cellular control mechanisms of exercise and atrophy encountered during relatively long-duration simulated microgravity. Funding Source: This research was supported by the National Aeronautics and Space Administration, NNJ06HF59G; the Institute for Translational Sciences at the University of Texas Medical Branch, supported in part by a Clinical and Translational Science Award (UR1TR000071) from the National Center for Advancing Translational Sciences, National Institutes of Health; the NASA Flight Analogs Project; and the Human Bioenergetic Program at Ball State University. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Supraphysiologic Testosterone Administration Impairs Late Osseointegration in Male Rats.

To evaluate the effect of supraphysiologic administration of testosterone in an early and late model of implant osseointegration in rat tibiae. A total of 40 rats were randomly allocated into four groups (n = 10/ group), which were divided according to the type of experiment and time of osseointegration: (1) vehicle (14 days), (2) testosterone (14 days), (3) vehicle (42 days), and (4) testosterone (42 days). Testosterone cypionate (7.5 mg/kg) administration started 4 weeks before implant placement, and the injections were performed daily until euthanasia. Machined-surface titanium implants (2.2 mm in diameter and 4 mm high) were placed bilaterally in the tibia of animals 28 days after the first testosterone injection. At days 14 and 42 after implant placement, euthanasia was performed and the tibiae were harvested to perform biomechanical evaluation and histomorphometric analysis of bone-to-implant contact (BIC%) and bone between the threads (BBT%). There was no statistical difference in the removal torque of the implants between the groups treated with the vehicle (control group) or testosterone (P > .05). At 14 days of osseointegration, the BIC% and BBT% did not differ between vehicle or testosterone groups (P > .05), while at 42 days, both the BIC% and BBT% were significantly reduced by testosterone compared to the vehicle group (P < .05). Testosterone cypionate in supraphysiologic dose impaired late-phase osseointegration in rat tibiae.

Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial.

To determine the effect of testosterone vs placebo treatment on health-related quality of life (HR-QOL) and psychosocial function in men without pathologic hypogonadism in the context of a lifestyle intervention. Secondary analysis of a 2-year randomized controlled testosterone therapy trial for prevention or reversal of newly diagnosed type 2 diabetes, enrolling men ≥ 50 years at high risk for type 2 diabetes from 6 Australian centers. Injectable testosterone undecanoate or matching placebo on the background of a community-based lifestyle program. Self-reported measures of HR-QOL/psychosocial function. Of 1007 participants randomized into the Testosterone for Type 2 Diabetes Mellitus (T4DM) trial, 648 (64%) had complete data available for all HR-QOL/psychosocial function assessments at baseline and 2 years. Over 24 months, while most measures were not different between treatment arms, testosterone treatment, compared with placebo, improved subjective social status and sense of coherence. Baseline HR-QOL/psychosocial function measures did not predict the effect of testosterone treatment on glycemic outcomes, primary endpoints of T4DM. Irrespective of treatment allocation, larger decreases in body weight were associated with improved mental quality of life, mastery, and subjective social status. Men with better baseline physical function, greater sense of coherence, and fewer depressive symptoms experienced greater associated decreases in body weight, with similar effects on waist circumference. In this diabetes prevention trial, weight loss induced by a lifestyle intervention improved HR-QOL and psychosocial function in more domains than testosterone treatment. The magnitude of weight and waist circumference reduction were predicted by baseline physical function, depressive symptomology, and sense of coherence.

(334) Worldwide Interest in Testosterone Replacement Therapy

Abstract Introduction Testosterone therapy has gained popularity in recent decades, with various methods of administration available, such as oral, topical, injection, and implantable routes. As a wider variety of treatment options arise, knowledge regarding the public interest in varying modalities may give providers an insight to patient preferences and assist in the counseling of patients seeking to initiate testosterone replacement therapy. Objective To examine public interest in the different methods of testosterone administration across the United States and compare their relative popularity to intramuscular injections. Methods Utilizing Google Trends, data pertaining to searches related to diverse testosterone administration methods were collected over a ten-year duration. The categories under analysis encompassed 1) testosterone injections, 2) implanted testosterone, 3) oral testosterone, and 4) topical testosterone. Controlled search terms, including news and weather queries, were employed. Search term trends were quantified in arbitrary units (a.u.) and plotted against the corresponding time period. Results Testosterone injection had the highest average search intent from Google Trends during the past 10 years (63.08 +/- 12.7 a.u.), followed by testosterone pills (60.56 +/- 13.4 a.u.), testosterone pellets (53.14 +/- 19.4 a.u.), testosterone patches (51.03 +/- 16.2 a.u.), and lastly testosterone gel (17.29 +/- 21.5 a.u.) A notable upward trend was recorded for all searches, with the highest increase in searches seen for implanted testosterone (m = 0.433), testosterone injections (m = 0.297), oral testosterone (m = 0.222), and lastly topical testosterone (m = 0.050) (Figure 1). Conclusions This study provides compelling evidence that all modes of testosterone administration had increasing search trends, most notably implantable testosterone therapies followed by testosterone injections, and oral testosterone, which may be in line with recent FDA approvals since 2019 for newer oral (Jatenzo, Tlando, Kyzatrex) and implantable (ex: Xyosted) options. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Antares Pharma, Clarus Therapeutics, Coloplast.

Network pharmacology analysis and experimental evaluations of YH complex on androgenetic alopecia by regulating the androgenic‐apoptotic axis

AbstractCinnamomum cassia and Astragalus membranaceus have been used as traditional medicines as well as functional foods worldwide, but its hair growth properties have been verified yet. This study was designed that possible molecular mechanism of YH complex consisting of C. cassia and A. membranaceus on androgenetic alopecia (AGA) was predicted and investigated in mice. Target genes of C. cassia and A. membranaceus constructed the YH complex network. AGA mice were induced by injection of testosterone and 100 and 150 mg/kg of YH complex were orally administered. From result of network analysis, the possible underlying mechanism of YH complex was closely related with the “regulation of hair cycle” and “apoptosis signaling pathway.” In depilated AGA mice, YH complex markedly promoted hair regrowth. Histological recovery on size and shape of hair follicles was appeared by YH complex administration. The expressions of 5α‐reductase and TGF‐β were significantly decreased in dorsal skin tissues of YH complex‐treated mice. Antiapoptotic Bcl‐2/Bax ratio was upregulated, while caspase activation was downregulated by treatment with YH complex. In summary, YH complex regulated hair development cycle by inhibiting the androgenic‐apoptotic axis in AGA. YH complex would be a potent therapeutic agent for alopecia.

P-40 A rare cause of male infertility: 46, XX testicular disorder of sex development

Abstract Introduction 46, XX testicular disorder of sex development (DSD) is a rare condition with an estimated incidence of 1 per 20,000 individuals. The clinical spectrum ranges from ambiguous genitalia that is usually diagnosed at birth, to male infertility that is diagnosed in the adult years. However, the diagnosis of 46, XX DSD in an individual presenting with infertility may be challenging due to occult clinical findings. A thorough physical examination as well as clinical suspicion is required for diagnosis. Clinical Case A 22-year-old male presented to the urology clinic for infertility despite at least 3 years of regular unprotected intercourse. On physical examination, his testicles were palpable bilaterally in the scrotum with small volumes. Laboratory results revealed hypergonadotropic hypogonadism and his spermiogram revealed azoospermia. Abdominopelvic ultrosonagraphy (US) was reported normal except abdominal situs inversus. Tumor markers for a probable testicular tumor were negative. He was referred to medical genetic department. His family history was unremarkable except for parental consanguineouty. The chromosomal analyze revealed a 46, XX karyotype, and fluorescence in situ hybridization (FISH) disclosed that the SRY gene locus was translocated to the X chromosome: 46,x,der(x) t(x;Y) (sry+); SRY + AZF a,b,c microdeletion. The patient was consulted to the endocrinology department for further evaluation of hypogonadism. On physical exam, he had eunuchoid habitus with incomplete virilization, bilateral and symmetric gynecomastia. The height, and body mass index of the patient was 165 cm, and 29.2 kg/m2, respectively. The testicles were bilaterally palpable in the scrotum, with a volume of 4 mL each. His luteinizing hormone (LH), follicle-stimulating hormone (FSH) and total testosterone levels were 14 mUI/mL (laboratory reference: 1.5–9 mUI/mL), 42 mUI/mL (1.4–18 mUI/mL), and 140 ng/dl (197-700 ng/dL), respectively. The bone age matched his chronological age. Bone densitometry revealed osteopenia. A direct X-ray of the thorax showed thoracic situs inversus, he diagnosed with situs inversus totalis. Detailed genetic analyses could not be done concerning this diagnosis due to financial constraints. He had no history of lung infections that ruled out Kartagener's syndrome. Treatment was started with monthly intramuscular testosterone injections of 250 mg/ml. The patient and his family received genetic counseling, including advice that assisted reproduction will not work owing to AZFabc deletion. Conclusion 46, XX DSD is an uncommon genetic disorder that is rarely identified during the evaluation of male infertility. Clinical suspicion and a comprehensive physical exam are keys for diagnosis. Genetic analysis is essential for definitive diagnosis. A multidisciplinary is required for treatment and follow-up. Psychological support and genetic counseling are also critical for the management of these patients.

In ovo injection of testosterone to yolk sac modulates early posthatching development and physiology of male chick in broilers

The aim of this study was to investigate the effects of in ovo testosterone injection into the yolk sac of embryos on physiology and development of broiler chicks during the early posthatching period. A total of 1,010 hatching eggs were obtained from the Ross genotype. Trial design was conducted with a noninjected group (control) and injection groups in which 100 µL sesame oil, or 100 µL sesame oil + 0.50 µmol testosterone were injected into the yolk sac of the embryo on d 6 or d 12 of incubation. Testosterone hormone level was measured in the egg yolk and albumen at onset of incubation, in the yolk sac on d 19 of incubation and in the residual yolk sac at hatching. Weights of chick, yolk sac and organ, morphological traits (body length, lengths of bilateral traits and beak length), asymmetrical development of bilateral morphological traits and body mass index were measured at hatching and on d 7 after hatching. Testosterone, corticosterone and growth hormone levels were determined in blood plasma obtained from male chicks at hatching and on d 7 of chick age. Chick weight was not affected, plasma testosterone level and brain weight decreased, while body mass index, plasma corticosterone and growth hormone levels increased by administering 0.50 µmol testosterone on d 12 of embryonic age. However, plasma testosterone and growth hormone levels did not change, chick weight increased, while plasma corticosterone level and the chick body length decreased by administering 0.50 µmol testosterone on d 6 of embryonic age. A significant interaction between chick age and in ovo testosterone administration resulted in an increase in lung weight of chicks. In conclusion, this study found that in ovo testosterone administered at different embryonic ages due to age-specific effects of testosterone in the yolk sac of embryo modulates development related to physiological parameters of male broiler chicks during early posthatching period.

Reversible effect of castration induced hypogonadism on the morphology of the left coronary arteries in adult male rabbits.

Hypogonadism is associated with an increased risk of coronary artery disease. This study sought to describe the histomorphology of the left coronary arteries of the adult male rabbit following orchiectomy and subsequent testosterone administration. We included 20 adult male rabbits, divided into a baseline group (n=2), an interventional group subjected to castration only (n=6), an intervention group subjected to castration followed by testosterone injection (n=6), and a control group (n=6). Key variables under investigation were serum testosterone levels, the intima-media thickness of coronary arteries, smooth muscle cell density, and adventitial collagen fiber density. The mean coronary arteries' intimal medial thickness was significantly higher in the castrated group than in controls (0.488 mm and 0.388 mm, respectively), while the testosterone-injected group had a mean of 0.440 mm. Mean smooth muscle cell density was significantly lower in the castrated rabbits vs. controls (26.96% and 47.80%, respectively), this observation being reversed with testosterone injection (47.53%). Mean adventitial collagen fiber density was significantly higher in the castrated group than in controls (66.6% and 36.1%, respectively), with a marginal difference after testosterone injection (65.2%). This study demonstrates that castration-induced hypogonadism causes morphological changes in the coronary arteries that are partly reversible using testosterone injections. These findings provide a morphological basis for understanding the role of testosterone in coronary arteries.

Effectiveness of selenium in maintaining morphological architecture of prostatic compartments in mongolian gerbil

Male prostate is a reproductive gland that is under steroid hormones influence, which is object of several studies related to proliferative lesions that may arise during the aging process. Selenium is a micro-nutrient that has been described as a toxic mineral if administered at high concentrations but can also be beneficial mineral exerting a protective action on various tissues used properly. This mineral can be found in some foods such as Brazil nuts, grains, cereals and some vegetables. Mongolian gerbil prostate have morphophysiological similarities between the human prostate and has been used for comparative studies. This work aims to analyze the morphology and stereology of Mongolian gerbil prostate after selenium supplementation, followed by testosterone injection. Animals were divided into 3 groups (5 per group): GC intact animals; TG testosterone injection (1 mg/kg) for 21 days; TSG, selenium administration and testosterone injection (1 mg/kg) for 21 days. After experimental phase, animals were euthanized and prostate was dissected, fixed in metacarn, embedded, and sections were stained with hematoxylin-eosin (HE) for morphological and morphometric/stereological analyses. Analyzes showed that prostate epithelium of TG showed points of stratification and higher columnar cells when compared to CG and TSG. Already stereological analysis showed that the volume of epithelium in TG and TSG was higher than in CG. Besides, non-muscular volume of TG stroma showed higher than in TSG and CG. In conclusion, selenium is, in this concentration, an important factor that acts in maintenance of prostate morphology, even under the influence of exogenous testosterone.

Akkermansia muciniphila promotes testosterone-mediated hair growth inhibition in mice.

The beneficial effects of Akkermansia muciniphila (Akk) on gut health and inflammation reduction have been demonstrated; however, scientific evidence of hair growth enhancement by Akk has not been reported. Therefore, this study was undertaken to investigate the effect of Akk on improving testosterone-mediated hair growth inhibition. Hair growth inhibition was induced through subcutaneous injection of testosterone into the shaved dorsal skin of C57BL/6 male mice. Live and pasteurized Akk were orally administered at a concentration of 1 × 108 colony-forming unit. After 5 weeks, hair length and skin tissues were analyzed. The live and pasteurized Akk significantly stimulated hair growth, countering the inhibitory effect of testosterone compared to the testosterone-alone group. Hematoxylin and eosin staining revealed a significant increase in hair follicle size in the Akk-treated group. An increase in β-catenin levels, which are associated with hair growth and cell cycle progression, was also observed. Moreover, the Akk-treated group exhibited increased levels of fibroblast growth factors, including Fgf7, Igf1, Fgf7, Fgf10, and Fgf21. However, no significant difference was observed between the live and pasteurized Akk groups. These results underscore the potential of live and pasteurized Akk in improving testosterone-mediated hair growth inhibition.